Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow
Tóm tắt
Treatment options for metastatic renal cell carcinoma (mRCC) have improved over recent years. Various therapies for metastatic renal cell carcinoma are currently approved for first and successive lines. Having various treatment options makes it important to reflect how patients experience side effects in the real-world setting. So far, data on the side effects of these treatments have only been collected within clinical trials, and have been mostly assessed by the investigator and not as patient-reported outcomes. Our aim was to determine patient-reported experiences of side effects in the real-world setting and to evaluate the doctor-patient communication regarding side effects. Data were collected via an anonymous, voluntary online survey given to members of a support group for RCC; the questionnaire was completed by 104 mRCC patients. 89.1% of participants were suffering from side effects of any grade. These appeared to be higher for patients treated with tyrosine kinase inhibitors compared to those treated with immune-checkpoint inhibitors (98.4% vs. 68.4%). However, information on side effects is scarce: 4.0% had never heard anything about them while only 18.8% of participants received detailed information on possible side effects. Although 85.6% of participants reported side effects to their physician, 34.6% did not encounter an improvement. Limitations of the study include the design as an online questionnaire and the small sample, consisting only of members of a support group. Differences can be seen between patient-reported side effects within our survey and those based on clinical trials. A shift towards more patient-reported outcomes is needed. In addition, patients seeking the advice of their physician on side effects are in need of more—or better—information and support.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Karner C, Kew K, Wakefield V, Masento N, Edwards SJ (2019) Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. BMJ Open 9(3):e024691. https://doi.org/10.1136/bmjopen-2018-024691
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V et al (2019) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(5):706–720. https://doi.org/10.1093/annonc/mdz056
Powles T (2021) Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):422–423. https://doi.org/10.1016/j.annonc.2020.11.016
Choueiri TK, Powles T, Burotto M, Bourlon MT, Zurawski B, OyervidesJuárez VM et al (2020) 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol 31:S1159. https://doi.org/10.1016/j.annonc.2020.08.2257
Motzer RJ, Tannir NM, McDermott DF, ArénFrontera O, Melichar B, Choueiri TK et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714
Peipert J, Zhao F, Lee J-W, Hong F, Ip E, Gareen IF et al (2020) Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients. JCO 38(15_suppl):e19136–e19136. https://doi.org/10.1200/JCO.2020.38.15_suppl.e19136
Bæksted CW, Nissen A, Knoop AS, Pappot H (2019) Patients’ experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy. Res Involv Engagem 20(5):36. https://doi.org/10.1186/s40900-019-0171-1.PMID:31832240;PMCID:PMC6868829
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh Q-D, Briganti A et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362
RKI - Zentrum für Krebsregisterdaten. Krebsdaten Nierenkrebs
Manz KM, Fenchel K, Eilers A, Morgan J, Wittling K, Dempke WCM (2020) Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. Adv Ther 37(2):730–744. https://doi.org/10.1007/s12325-019-01167-2
Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S et al (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93–113. https://doi.org/10.1093/jnci/djr511
Tan Q, Wang W, Long Y, Chen G (2015) Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: a meta-analysis. Exp Ther Med 9(6):2275–2280. https://doi.org/10.3892/etm.2015.2427
Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP et al (2017) ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 36(5):1187–1196. https://doi.org/10.1016/j.clnu.2017.06.017
Makaroff L, de Lorenzo F, Apostolidis K, Pelouchova J, Winterbottom A, Chrostowski S et al (2017) The European cancer patient Coalition’s white policy paper on the value of innovation in oncology. Ann Oncol 28:v511. https://doi.org/10.1093/annonc/mdx385
Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M et al (2015) Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 136(1):1–10. https://doi.org/10.1002/ijc.28715
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823. https://doi.org/10.1056/NEJMoa1510016
Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O et al (2013) Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. JCO 31(30):3791–3799. https://doi.org/10.1200/JCO.2012.47.4940
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. https://doi.org/10.1016/S0140-6736(11)61613-9
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. https://doi.org/10.1056/NEJMoa1303989
Escudier B, Eisen T et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 357(2):203. https://doi.org/10.1056/NEJMx070012
Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA (2013) Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol 18(6):1060–1069. https://doi.org/10.1007/s10147-012-0497-2
Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ et al (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24(8):3669–3676. https://doi.org/10.1007/s00520-016-3297-9
Brent S, Padula A, Avins A (2006) Brief_communication_better_ways_to_quest. Ann Intern Med 144(4):257–61
Ioannidis JPA, Mulrow CD, Goodman SN (2006) Adverse events: the more you search, the more you find. Ann Intern Med 144(4):298–300. https://doi.org/10.7326/0003-4819-144-4-200602210-00013
Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A et al (2020) Importance of and satisfaction with information about their disease in cancer patients. J Cancer Educ 35(2):403–411. https://doi.org/10.1007/s13187-019-1480-7
Rudolph I, Seilacher E, Köster M-J, Stellamanns J, Liebl P, Zell J et al (2015) Der informationsbedarf von Patienten mit Krebserkrankungen in Deutschland–eine befragung von Patienten und Angehörigen. Dtsch Med Wochenschr 140(5):e43–e47. https://doi.org/10.1055/s-0041-100585